SCHEMBL4548904

SCHEMBL4548904

CNc1cc(Oc2ccc3c(C(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)cccc3c2)ccn1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.75
FLT1 P17948 4/20 0.58
FLT4 P35916 4/20 0.58
RET P07949 3/20 0.56
RAF1 P04049 5/20 0.55
BRAF P15056 3/20 0.55
PDGFRB P09619 2/20 0.55
KIT P10721 2/20 0.55
FGFR1 P11362 2/20 0.55
MEN1 O00255 1/20 0.55
PLK4 O00444 1/20 0.55
CIT O14578 1/20 0.55
AURKA O14965 1/20 0.55
MUSK O15146 1/20 0.55
EPHB6 O15197 1/20 0.55
MAPK13 O15264 1/20 0.55
MLNR O43193 1/20 0.55
MAP3K7 O43318 1/20 0.55
RIPK2 O43353 1/20 0.55
DYRK3 O43781 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748040 0.89 KDR (0.75) KDRFLT1FLT4RETRAF1
SCHEMBL4548992 0.88 KDR (0.72) KDRFLT1FLT4RETRAF1
SCHEMBL4548902 0.87 KDR (0.81) KDRFLT1FLT4BRAFFGFR1
SCHEMBL2748395 0.87 KDR (0.75) KDRFLT1FLT4RETBRAF
SCHEMBL4548898 0.86 KDR (1.00) KDRFLT1FLT4BRAFFGFR1
SCHEMBL4548896 0.85 KDR (0.78) KDRFLT1FLT4RETRAF1
SCHEMBL4548910 0.85 KDR (0.84) KDRFLT1FLT4BRAFFGFR1
SCHEMBL2436244 0.83 KDR (0.83) KDRFLT1FLT4RETRAF1
SCHEMBL4548897 0.83 KDR (0.84) KDRFLT1FLT4BRAFFGFR1
SCHEMBL2748198 0.83 KDR (0.84) KDRFLT1FLT4BRAFFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885FLT1 89/4885FLT4 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.